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Colin Church, PhD; Carlos Celis-Morales, PhD; Ian C.K. Wong, PhD;
Colin Berry, PhD; Naveed Sattar, PhD; and Jill P. Pell, MDAbstract
Objective: To assess the associations between coronavirus disease 2019 (COVID-19) infection and
thromboembolism including myocardial infarction (MI), ischemic stroke, deep vein thrombosis
(DVT), and pulmonary embolism (PE).
Patients and Methods: A self-controlled case-series study was conducted covering the whole of
Scotland’s general population. The study population comprised individuals with confirmed (positive
test) COVID-19 and at least one thromboembolic event between March 2018 and October 2020. Their
incidence rates during the risk interval (5 days before to 56 days after the positive test) and the control
interval (the remaining periods) were compared intrapersonally.
Results: Across Scotland, 1449 individuals tested positive for COVID-19 and experienced a throm-
boembolic event. The risk of thromboembolism was significantly elevated over the whole risk period
but highest in the 7 days following the positive test (incidence rate ratio, 12.01; 95% CI, 9.91 to 14.56)
in all included individuals. The association was also present in individuals not originally hospitalized
for COVID-19 (incidence rate ratio, 4.07; 95% CI, 2.83 to 5.85). Risk of MI, stroke, PE, and DVT were
all significantly higher in the week following a positive test. The risk of PE and DVT was particularly
high and remained significantly elevated even 56 days following the test.
Conclusion: Confirmed COVID-19 infection was associated with early elevations in risk with MI,
ischemic stroke, and substantially stronger and prolonged elevations with DVT and PE both in hos-
pital and community settings. Clinicians should consider thromboembolism, especially PE, among
people with COVID-19 in the community.
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the end of this article.I ncreasing evidence suggests a potentiallink between coronavirus disease 2019(COVID-19) infection and thromboem-
bolism, which could affect a range of organs
resulting in myocardial infarction (MI),
ischemic stroke, pulmonary embolism (PE),
and deep vein thrombosis (DVT).
First indications of a potential link
came from a case report that described PE
in a patient infected with COVID-19 who
had no relevant risk factors or past medical
history.1 Subsequently, hospital-based caseMayo Clin Proc. n October 2021;96(10):2587-2597 n https://doi.org
www.mayoclinicproceedings.org n ª 2021Mayo Foundation for Med
the CC BY license (http://creativecommons.org/licenses/by/4.0/).series supported the hypothesis, including
ischemic stroke in five younger (33-49
years) patients who tested positive for
COVID-19.2 A recent meta-analysis of
3487 COVID-19 patients from 30 studies
produced a 26% pooled incidence of
venous thromboembolism, but concluded
that the existing evidence was low-quality
and heterogeneous.3 Similar findings were
reported by another meta-analysis focused
on PE and DVT.4 Venous thromboembo-
lism has now been recognized as a/10.1016/j.mayocp.2021.07.002
ical Education and Research. Published by Elsevier Inc. This is an open access article under
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2588relatively common complication of
COVID-19 and clinical guidelines recom-
mend the use of pharmacological prophy-
laxis following risk assessment.5 However,
clinical trials have provided heterogenous
findings, potentially depending on the
severity of COVID-19.6,7
The current evidence, however, is mainly
based on crude incidence from hospitalized
case series. Because hospitalized patients
are a highly selected minority of those
infected with COVID-19, these studies are
unrepresentative and not generalizable to
the general population.8 It is unknown
whether people who are asymptomatic or
who have mild COVID-19 symptoms
(nonhospitalized) were also at a higher risk
of thromboembolic events. Even in studies
comparing thromboembolic risk between in-
dividuals with and without COVID-19,9 un-
observed confounding is still a major
concern. To address these limitations, we
conducted a self-controlled case series
(SCCS) study using a national, general pop-
ulation cohort. This method overcomes bias
due to unobserved health conditions.
Because an SCCS is conducted only among
people with any thromboembolic events,
we conducted a supplementary cohort anal-
ysis to verify the findings.PATIENTS AND METHODS
Data Sources
We undertook individual-level record link-
age of five health databases covering the
whole of Scotland (population, 5.5 million)
between March 2018 and October 2020:
The Community Health Index (CHI) regis-
ter, Electronic Communication of Surveil-
lance in Scotland (ECOSS), Rapid
Preliminary Inpatient Data (RAPID), Scot-
tish Morbidity Record 01 (SMR01), and
death certificates.
The CHI register provides sociodemo-
graphic information (age, sex, area socio-
economic deprivation). Deprivation is
measured using the Scottish Index of Multi-
ple Deprivation (SIMD), derived from seven
domains d income, education, health,
employment, crime, housing, and access toMayo Clin Proc. n October 2021;9services d and categorized into general
population quintiles. The ECOSS collects
laboratory data on infectious diseases,
including test date and result. The RAPID
collects real-time data on hospitalization,
including dates of admission and discharge,
and type of ward; and SMR01 records dis-
eases using International Classification of
Diseases 10th Revision (ICD-10) codes and
procedures using Office of Population Cen-
suses and Surveys version 4 (OPCS-4)
codes. Death certificates provide the date
and cause (using ICD-10) of all deaths,
whether in hospital or the community.
The CHI, a unique identifier, is used across
all databases enabling exact matching. We
extracted records covering March 1, 2018,
to October 5, 2020, inclusive for all data-
bases except the ECOSS COVID-19 test
data which covered March 1, 2020, to
October 5, 2020. The Scottish data were
accessed through the Electronic Data
Research and Innovation Service, Public
Health Scotland, and have been used in
several previous epidemiological
studies.10,11 Approval for the study was
provided by the Public Benefit and Privacy
Panel for Health and Social Care (reference
2021e0064).
In the supplementary cohort analysis, all
individuals with a positive COVID-19 test
were included as the exposed group. For
each exposed individual, 10 age-, sex-, and
deprivation-matched individuals who did
not have a test positive were included using
probability density matching.Outcomes
This study included five outcomes ascer-
tained from SMR01 and death certificates:
MI (ICD-10: I21), ischemic stroke (I63-64),
PE (I26), and DVT (I80.1-80.9, I82.8, and
I82.9), as well as thromboembolism (com-
posite of all four). To test the specificity of
any association between COVID-19 and
thromboembolism, we also included a com-
posite negative control outcome of elective
surgery for hernia repair (OPCS-4 T19,
T21-27), colonoscopy (OPCS-4 H22, H25,
and H28), cataract surgery (OPCS-4 C71-6(10):2587-2597 n https://doi.org/10.1016/j.mayocp.2021.07.002
www.mayoclinicproceedings.org
THROMBOEMBOLIC RISK IN COVID-19 PATIENTS75, C77, and C79), or hip/knee replacement
(OPCS-4 W37-42, W93-95, and O18).
Statistical Analyses
The SCCS method was chosen to analyze
the association between COVID-19 infec-
tion and outcomes (Supplementary
Figure 1, available online at http://www.
mayoclinicproceedings.org), in favor of a
traditional cohort approach because of its
ability to control for intrapersonal time-
invariant confounders, and the United
Kingdom’s testing strategy. Frail individ-
uals with long-term conditions were more
likely both to be tested and experience
adverse outcomes. These confounders may
not be well recorded in the routine data.
With a new condition, such as COVID-19,
other unknown confounders may also exist.
The SCCS method eliminates intrapersonal
time-invariant confounders because each
person acts as their own control.12 The
method has been widely used in epidemio-
logical studies, including a study on influ-
enza and MI.13
The study population comprised
everyone in Scotland who had confirmed
(positive real-time polymerase chain reac-
tion test) COVID-19 infection and had expe-
rienced one or more thromboembolic event
over the study period. The incidence rate ra-
tio (IRR) of thromboembolic outcomes was
derived from the ratio of incidence rates in
risk and control intervals. The risk interval
was defined as between 5 days before and
54 days after the sample was obtained for
their first positive COVID-19 test. The risk
interval was categorized into groups accord-
ing to 5 to 1 day before, 0 to 7 days after, 8 to
28 days after, and 29 to 56 days after. The 5
days before confirmed infection patients
were included in the risk period to take ac-
count of lags in symptom development and
testing. The control interval was defined as
the remaining study period. Because the
UK COVID-19 pandemic started in March
2020, the majority of the control interval
occurred before infection.
Conditional Poisson regression was used
adjusting for participant age in quintileMayo Clin Proc. n October 2021;96(10):2587-2597 n https://doi.org
www.mayoclinicproceedings.orggroups, the main time-varying confounder.
Deriving rates for both the risk and control
intervals from the same individual obviated
the need to control statistically for time-
invariant confounders. Because individuals
who had fatal events before the pandemic
had not had a chance to take a COVID-19
test, standard SCCS cannot be applied to
fatal events, and the models were run
initially for nonfatal hospitalizations. We
then repeated the analyses for the composite
outcome of hospitalization or death using
the extended SCCS for event-dependent
observation periods, which was described
elsewhere.14
Subgroup analyses were conducted by
COVID-19 admission (those with COVID-
19 as primary diagnosis versus those
without), age (75 versus >75 years), sex,
and socioeconomic deprivation (SIMD quin-
tile 1-3 vs SIMD quintile 4-5). P values for
subgroup differences were calculated. Addi-
tional subgroup analysis was conducted for
age (65, 66-80, and >80 years) to explore
any age trends, even though the number of
events were not sufficient to conduct formal
tests. Three sensitivity analyses were con-
ducted. Firstly, seasonality in 3-month cate-
gories was adjusted because cardiovascular
diseases exhibit seasonal patterning. Sec-
ondly, we included an extended risk interval,
14 to 6 days before a positive test. If the
elevated risk in this extended interval is
lower than that in the immediate pretest in-
terval, reverse causation is less likely.
Thirdly, as COVID-19 infection was not
tested before the 2020 pandemic, we
restricted the analysis to cases with events
after February 1, 2020. Lastly, we calculated
the E values to investigate how robust our
findings are regarding time-varying con-
founders.15 A high E-value suggests that
only a strong time-varying confounder could
nullify the findings.
A supplementary cohort analysis was
conducted. Time-to-event (from testing pos-
itive in the exposed individual) to the
thromboembolic events was regressed by
positive COVID-19 test, controlling for age,
















FIGURE 1. Participant flo
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2590hazards model. Proportional hazards as-
sumptions were checked using the Schoen-
feld residuals. All analyses were conducted
in R version 3.5.1 with the packages SCCS
and survival.RESULTS
Of the 30,709 individuals who had at least
one positive COVID-19 test (Figure 1) be-
tween March 1, 2020, and October 5, 2020,
the incidence rates were 44.0, 67.0, 48.6,
and 18.8 per 1000 person-years for MI,
ischemic stroke, PE, and DVT, respectively.
The SCCS analysis further excluded 29,260
individuals because they did not have
thromboembolic events in the study period.
Of the 1449 individuals who had thrombo-
embolic events, 117 died out-of-hospital,















5 excluded due to being
the same COVID-19
episodes
29,260 excluded due to
not having the outcome
117 excluded due to
event ascertained from
death certificate only
81 excluded due to in-
hospital death
wchart. COVID-19, coronavirus disease 2019.
Mayo Clin Proc. n October 2021;9events. Less than one-third (31.5%) of the
individuals had a COVID-19 primary diag-
nosis in hospital. Among people with
nonfatal events, the median age was 77 years
(interquartile range, 65-85 years), half were
male, and 26.46% lived in the most deprived
quintile (Table 1). The median age was older
for ischemic stroke (82 years) and younger
for PE (71 years) and DVT (73 years).
Women accounted for a higher percentage
(58.6%) of those with DVT.
The risk of nonfatal thromboembolism
was significantly higher over the whole risk
interval and highest within the 7 days
following the positive test (IRR, 12.01; 95%
CI, 9.91 to 14.56) (Table 2). The associa-
tions were strongest for PE followed by
DVT (Figure 2), which had similar risk pat-
terns to overall thromboembolism. The asso-
ciations with MI and ischemic stroke were
smaller in magnitude but nonetheless signif-
icant in the 7 days following a positive test,
as well as the previous 5 days for MI only.
Except for MI, all IRRs in the 7-day post-
test interval were significantly stronger
than those in the pretest intervals (P<.04).
As expected, there was no significant change
in the risk of elective surgery before or after
a positive COVID-19 test. The findings for
the composite outcome of fatal and nonfatal
thromboembolism were similar to those for
nonfatal thromboembolism, after accounting
for censoring.
Adjusting for seasonality did not alter the
findings (Supplementary Table 1, available
online at http://www.mayoclinicproceedings.
org). The extended pretest risk interval
generally had lower IRRs than the immediate
pretest interval, and were nonsignificant for
MI, ischemic stroke, and PE. Including only
participants with thromboembolic events af-
ter February 2020 resulted in similar IRR es-
timates. The E values ranged from 5.53 (MI)
to 40.59 (PE) for the lower bound of 95% CIs
within 7 days of a positive test.
On subgroup analysis, the associations
between a positive test and thromboembo-
lism were significant regardless of COVID-
19 admission, even though the elevation of
risk was stronger among those admitted for
COVID-19 (Table 3). A positive COVID-196(10):2587-2597 n https://doi.org/10.1016/j.mayocp.2021.07.002
www.mayoclinicproceedings.org
TABLE 1. Patient Characteristics for Analysis of Nonfatal Admissionsa,b
Composite Myocardial infarction Ischemic stroke Pulmonary embolism Deep vein thrombosis Elective surgeryc
n for all events 1449 376 560 417 179 123
n for admissions only 1332 337 505 391 174 123
n for nonfatal admissions only 1251 319 473 359 169 116
COVID-19 as primary
diagnosis in admission episode
389 (31.5) 104 (32.6) 123 (26.0) 145 (40.4) 41 (26.6) 14 (12.1)
Median (IQR) age, y 77 (65-85) 78 (67-85) 82 (73-87) 71 (59-81) 73 (59-82) 78 (70-85)
Sex
Female 626 (50.04) 128 (40.13) 246 (52.01) 180 (50.14) 99 (58.58) 45 (38.79)
Male 625 (49.96) 191 (59.87) 227 (47.99) 179 (49.86) 70 (41.42) 71 (61.21)
SIMD quintile
1st (Most deprived) 331 (26.46) 91 (28.53) 124 (26.22) 84 (23.40) 47 (27.81) 34 (29.31)
2nd 282 (22.54) 79 (24.76) 100 (21.14) 88 (24.51) 32 (18.93) 21 (18.10)
3rd 230 (18.39) 55 (17.24) 94 (19.87) 65 (18.11) 33 (19.53) 21 (18.10)
4th 230 (18.39) 53 (16.61) 95 (20.08) 68 (18.94) 27 (15.98) 25 (21.55)
5th (Least deprived) 178 (14.23) 41 (12.85) 60 (12.68) 54 (15.04) 30 (17.75) 15 (12.93)
aCOVID-19, coronavirus disease 2019; IQR, interquartile range; SIMD, Scottish Index of Multiple Deprivation.
bn (%) are presented unless otherwise specified.
cElective surgery included hernia repair, colonoscopy, cataract surgery, and hip and knee replacement, and is a negative control outcome.
THROMBOEMBOLIC RISK IN COVID-19 PATIENTStest was also associated with higher risk of
thromboembolism regardless of age, but
the magnitude of risk was significantly
higher (Pinteraction<.0001) in people younger
than 75 years. Compared with people aged
older than 75 years, those younger had 23
and 47 times higher elevated thromboembo-
lism and PE risk, respectively, within 7 days
of a positive COVID-19 test (Table 3). There
appears to be a dose-response trend by age
even though insufficient sample size
inhibited formal testing (Supplementary
Table 2, available online at http://www.
mayoclinicproceedings.org). A positive
COVID-19 test was associated with higher
risk of overall thromboembolism, PE, and
DVT in both women and men, but the
magnitude of risk was higher in men
(Pinteraction<.006). The association between
a positive COVID-19 test and ischemic
stroke was significant in men only. There
was no consistent evidence of socioeconomic
deprivation being an effect modifier
(Supplementary Table 2).
The findings from cohort analysis were
consistent with those from SCCS. Individ-
uals who had a COVID-19 infection wereMayo Clin Proc. n October 2021;96(10):2587-2597 n https://doi.org
www.mayoclinicproceedings.orgat a higher risk of all of the outcomes, with
strongest association with PE (hazard ratio
[HR], 24.04; 95% CI, 18.49 to 31.33), fol-
lowed by DVT (HR, 10.45; 95% CI, 7.02 to
15.56), ischemic stroke (HR, 4.40; 95% CI,
3.44 to 5.63), and MI (HR, 3.31; 95% CI,
2.59 to 4.22).
DISCUSSION
In this national, general population study
including hospitalized and community-
dwelling individuals, we showed an elevated
risk of thromboembolism in temporal prox-
imity to confirmed COVID-19 infection. In
the week following a positive test, partici-
pants were at significantly increased risk of
MI, ischemic stroke, PE, and DVT, with the
increased risk of the latter two being marked
(day 0 to þ7 IRRs of >27- and >17-fold,
respectively) d with risk ratios substantially
exceeding those previously associated with
upper respiratory infections16 d and
elevated risk continuing for some time there-
after. The risk ratios were even higher in
younger people and in men. The clear impli-
cation of this work is that PE/DVT risks are
substantially elevated in hospitalized/10.1016/j.mayocp.2021.07.002 2591
TABLE 2. Associations Between COVID-19 and Outcomesa,b,c
Outcome by risk intervals
Nonfatal events All eventsd
IRR (95% CI) P IRR (95% CI) P
Composite
5-1 days before 4.77 (3.20-7.10) <.0001 3.71 (2.50-5.49) <.0001
0-7 days after 12.01 (9.91-14.56) <.0001 5.70 (4.72-6.89) <.0001
8-28 days after 2.82 (2.16-3.67) <.0001 1.54 (1.22-1.94) .0003
28-56 days after 2.30 (1.77-3.00) <.0001 1.51 (1.21-1.88) .0002
Myocardial infarction
5-1 days before 5.15 (2.54-10.46) <.0001 3.79 (1.86-7.71) .0002
0-7 days after 5.16 (3.04-8.73) <.0001 1.98 (1.23-3.18) .005
8-28 days after 1.51 (0.77-2.95) .23 0.85 (0.50-1.44) .55
28-56 days after 1.15 (0.56-2.35) .70 0.90 (0.53-1.50) .67
Ischemic stroke
5-1 days before 2.12 (0.88-5.13) .10 1.58 (0.65-3.84) .31
0-7 days after 7.22 (5.02-10.38) <.0001 3.25 (2.34-4.50) <.0001
8-28 days after 0.75 (0.35-1.58) .45 0.69 (0.42-1.12) .14
28-56 days after 1.11 (0.63-1.94) .72 0.94 (0.63-1.41) .77
Pulmonary embolism
5-1 days before 9.95 (5.42-18.27) <.0001 7.47 (4.13-13.51) <.0001
0-7 days after 27.55 (20.55-36.95) <.0001 16.81 (12.46-22.69) <.0001
8-28 days after 7.27 (5.07-10.43) <.0001 4.52 (3.21-6.35) <.0001
28-56 days after 5.59 (3.87-8.07) <.0001 3.54 (2.54-4.93) <.0001
Deep vein thrombosis
5-1 days before 4.67 (1.48-14.72) .008 4.23 (1.34-13.32) .01
0-7 days after 17.44 (11.00-27.66) <.0001 11.51 (7.30-18.16) <.0001
8-28 days after 3.64 (1.90-7.01) .0001 2.43 (1.27-4.67) .008
28-56 days after 1.98 (0.91-4.29) .08 1.77 (0.92-3.42) .09
Elective surgeriese
5-1 days before d d d d
0-7 days after 1.69 (0.41-6.88) .47 1.28 (0.40-4.06) .67
8-28 days after 1.78 (0.65-4.90) .26 0.94 (0.34-2.59) .91
28-56 days after 2.28 (0.98-5.32) .06 1.19 (0.51-2.76) .68
aCOVID-19, coronavirus disease 2019; IRR, incidence rate ratio.
bPatients’ age quintile was adjusted.
cBold type indicates P < .05
dIncluding both fatal and nonfatal events, with event-dependent observation handled using specialized method.
eElective surgery included hernia repair, colonoscopy, cataract surgery, and hip/knee replacement, and is a negative control outcome.
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2592patients as compared with more modest and
shorter atherothrombotic risks. However,
there appears a broader thrombotic impact
not confined to hospitalized populations,
albeit at a lower risk level.
The associations were also significant in
individuals not hospitalized for COVID-19.
Although the IRRs were modest compared
with the hospitalized group, the excess risk
for PE was sustained at near three-fold for
more than 1 to 2 months after the initial
COVID-19 infection. This modest excess
risk may also be applicable to a large numberMayo Clin Proc. n October 2021;9of people who were infected with COVID-19
but not hospitalized, which could mean a
sizeable population burden. The annual inci-
dence of PE in the UK general population
was 0.98 per 1000.17 If the IRR on this study
(3.92 in the first 7 days of the nonhospital-
ized group) is applicable to the general pop-
ulation, this would translate to a rate
difference of 3.84 in 1000. There were 4.27
million people who tested positive for
COVID-19 in the UK as of March 16, 2021,
indicating that at least 16,400 new PE cases









































FIGURE 2. Associations between COVID-19 and nonfatal outcomes. Incidence rate ratio (IRR) shown is
the within IRR for outcomes. Incidence rates in the risk period (5 days before 56 after a positive coro-
navirus disease 2019 [COVID-19] test) were compared against the control period (all remaining time in
study period) for each person.
THROMBOEMBOLIC RISK IN COVID-19 PATIENTSAt the present time, unpublished results
from intensive care unit COVID-19 popula-
tions have led to early stopping of anticoag-
ulant therapeutic arms because of signals
suggestive of harm.6 Conversely, the same
collated international studies have intimated
a significant decreased need for life support
and improved results from less severe hospi-
talized patients.7 Such heterogenous results
could be related to the severity of COVID-
19, as well as the timing of administering
pharmacologic prophylaxis. Given the
potentially treatable nature of thrombotic
events, urgent work must be undertaken in
prevention and treatment trial design to a
consider risk stratification strategy that in-
cludes COVID-19 severity, age, and sex.
Our new findings are in line with but
meaningfully extend previous COVID-19
studies, including another national cohort
from Denmark.9 A meta-analysis of more
than 100,000 COVID-19 patients reported
that 1.2% developed ischemic stroke18; a
large proportion even considering their ageMayo Clin Proc. n October 2021;96(10):2587-2597 n https://doi.org
www.mayoclinicproceedings.organd vascular risk profile. A hospital-based
case-control study of 123 patients found an
association (odds ratio, 3.9) between
COVID-19 infection and acute ischemic
stroke, after controlling for age, sex, and
vascular risk factors.19 Similarly, two meta-
analyses reported high rates of PE and DVT
in patients with COVID-19.3,4 Traditional
thromboembolic risk factors were not signif-
icantly associated with PE in COVID-19 pa-
tients, suggesting that the pathways may be
different.20 Previous studies21 have shown
that the PE found in severe COVID-19 pa-
tients might actually be primarily caused by
pulmonary thrombi rather than pulmonary
emboli, which warrants further
investigation.
This study’s association pattern for MI is
similar to that for influenza, with five to six
times higher risk in the first 7 days after a
positive test.13 However, the association of
COVID-19 with venous thromboembolism
appeared to be much stronger than that of
other infections. For example, a study using/10.1016/j.mayocp.2021.07.002 2593
TABLE 3. Subgroup Analysis for Nonfatal Eventsa,b,c
Outcome by risk intervals






PinteractionIRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI)
Composite
5-1 days before 12.45 (7.37-21.03) 2.48 (1.33-4.63) .0001 3.80 (2.44-5.93) 2.60 (1.81-3.72) .19 2.22 (1.41-3.47) 4.31 (3.02-6.15) .03
0-7 days after 36.97 (28.69-47.64) 4.07 (2.83-5.85) <.0001 22.78 (17.58-29.53) 5.94 (4.35-8.12) <.0001 6.36 (4.47-9.04) 19.44 (15.38-24.58) <.0001
8-28 days after 6.16 (4.18-9.09) 1.82 (1.26-2.63) <.0001 5.79 (4.16-8.07) 1.24 (0.78-1.97) <.0001 2.64 (1.83-3.82) 3.19 (2.18-4.66) .50
28-56 days after 4.85 (3.27-7.20) 1.50 (1.04-2.17) <.0001 4.27 (3.03-6.03) 1.12 (0.72-1.74) <.0001 2.28 (1.59-3.27) 2.46 (1.66-3.65) .79
Myocardial infarction
5-1 days before 3.58 (0.86-14.88) 6.17 (2.73-13.95) .52 4.14 (2.00-8.54) 3.36 (1.80-6.26) .67 4.29 (2.15-8.58) 3.47 (1.82-6.60) .66
0-7 days after 8.09 (3.87-16.90) 3.38 (1.50-7.65) .12 6.19 (2.85-13.42) 3.65 (1.69-7.88) .34 3.35 (1.22-9.18) 6.45 (3.46-12.00) .28
8-28 days after 1.00 (0.24-4.17) 1.85 (0.86-3.96) .46 2.49 (1.08-5.77) 0.77 (0.24-2.45) .11 1.58 (0.57-4.39) 1.43 (0.58-3.50) .89
28-56 days after 1.28 (0.39-4.22) 1.15 (0.47-2.81) .89 1.01 (0.32-3.23) 0.97 (0.35-2.64) .96 1.41 (0.51-3.92) 0.94 (0.34-2.57) .60
Ischemic stroke
5-1 days before 3.23 (0.79-13.30) 1.62 (0.52-5.06) .45 1.70 (0.54-5.39) 1.84 (1.00-3.37) 1.00 1.21 (0.50-2.96) 2.58 (1.32-5.08) .18
0-7 days after 14.03 (8.11-24.27) 4.22 (2.50-7.12) .0019 17.81 (10.67-29.72) 3.63 (2.07-6.38) <.0001 2.05 (0.84-5.00) 13.27 (8.79-20.04) .0002
8-28 days after 1.26 (0.39-4.07) 0.51 (0.19-1.37) .25 0.45 (0.06-3.27) 0.81 (0.36-1.84) 1.00 0.75 (0.28-2.03) 0.72 (0.23-2.26) .96
28-56 days after 2.37 (1.06-5.29) 0.60 (0.27-1.36) .02 1.46 (0.53-4.02) 0.93 (0.47-1.83) .47 1.20 (0.59-2.45) 0.96 (0.39-2.37) .75
Pulmonary embolism
5-1 days before 50.25 (24.26-104.07) 2.09 (0.52-8.44) .0001 5.36 (2.60-11.08) 3.40 (1.64-7.03) .39 1.98 (0.73-5.37) 8.10 (4.42-14.86) .02
0-7 days after 135.97 (88.89-207.98) 3.92 (1.83-8.40) <.0001 46.84 (32.21-68.12) 10.36 (5.99-17.91) <.0001 15.22 (9.30-24.90) 43.82 (29.78-64.48) .001
8-28 days after 23.97 (14.03-40.97) 3.54 (2.03-6.16) <.0001 12.64 (8.20-19.49) 2.04 (0.93-4.48) .0001 5.77 (3.42-9.71) 9.35 (5.63-15.54) .20
28-56 days after 16.26 (9.35-28.27) 2.99 (1.74-5.15) <.0001 8.13 (5.16-12.81) 1.88 (0.90-3.94) .0009 4.98 (3.02-8.21) 6.21 (3.58-10.77) .57
Deep vein thrombosis
5-1 days before 24.07 (5.54-104.49) 1.82 (0.25-13.20) .04 2.20 (0.54-9.04) 3.83 (1.51-9.69) 1.00 3.18 (1.16-8.73) 3.90 (1.20-12.65) .80
0-7 days after 92.44 (46.02-185.68) 3.77 (1.36-10.46) <.0001 24.21 (13.13-44.64) 10.59 (5.11-21.97) .09 8.04 (3.49-18.57) 33.91 (18.80-61.18) .006
8-28 days after 9.54 (3.15-28.93) 2.75 (1.18-6.40) .08 5.30 (2.38-11.80) 1.74 (0.53-5.68) .13 4.89 (2.33-10.26) 2.03 (0.49-8.45) .33
28-56 days after 1.46 (0.19-11.55) 2.35 (1.01-5.46) .67 2.85 (1.11-7.28) 0.91 (0.22-3.82) .19 1.41 (0.44-4.50) 3.49 (1.23-9.90) .26
aCOVID-19, coronavirus disease 2019; IRR: incidence rate ratio.
bPatients’ age quintile was adjusted.






























THROMBOEMBOLIC RISK IN COVID-19 PATIENTSthe same SCCS method found the elevated
risk of DVT was much lower (IRR, 1.91 in
the first 2 weeks) for upper respiratory infec-
tions.16 The same study also found that the
risk of PE elevated (IRR, 2.11 in the first 4
weeks) following urinary tract infection.
These suggest that COVID-19 may have
either different mechanisms, or a stronger
systemic inflammation (in keeping with the
cytokine storm), leading to an exponential
difference in the risk of PE/DVT compared
with other infections, while having similar
elevation in MI risk.
Our study showed that the association
with ischemic stroke was significantly stron-
ger in younger (75 years) individuals. This
is consistent with previous reports of rela-
tively young people (mean age, 53 to 60
years) with COVID-19 requiring thrombec-
tomy.22-24 In addition, among stroke pa-
tients, those who tested positive for
COVID-19 were on average 7 to 15 years
younger than those who tested negative.25,26
The underlying mechanism warrants further
investigation but could relate to cytokine
storm, at least in some people.27 Historical
reports showed that healthy young people
were more likely to experience cytokine
storm following viral infections,27 and cyto-
kine storm in COVID-19 patients leading
to hypercoagulability was a hypothesized
mechanism for thromboembolism.28 The
finding that COVID-19 is associated with a
higher risk of thromboembolism in men
than women may partially explain our previ-
ous finding that men have worse case fatality
following COVID-19 infection.29 This hy-
pothesis requires further study.
Our study has several strengths. Firstly,
it was unselective, covering the whole of
Scotland and all confirmed COVID-19 cases
regardless of whether they were hospitalized.
This avoided the selection bias intrinsic to
hospital-based studies. Because both
COVID-19 infection and thromboembolism
increase the chance of hospitalization, select-
ing only hospital cases inevitably results in
collider bias.8 Secondly, time-invariant con-
founders, including unknown and unmea-
sured confounders, were perfectly
controlled by using participants as theirMayo Clin Proc. n October 2021;96(10):2587-2597 n https://doi.org
www.mayoclinicproceedings.orgown controls. The key time-varying con-
founders, age and seasonality, were adjusted
for in the model.12 The use of E-values
showed that the elevated risk within 7 days
of a positive test would only be meaningfully
nullified if there were very strong time-
varying confounders that could increase/
decrease the risk of positive test and throm-
boembolic events by 5 to 20 times. Thirdly,
we were able to separately analyze nonfatal
events using the standard SCCS method,
and all events, using a specific method
designed for censored data.14 The two ap-
proaches produced consistent findings.
This, along with the sensitivity analysis
including only events shortly before the
COVID-19 pandemic, suggest that the re-
sults should be robust against immortal
time biases.
However, the findings of this study are
still subject to the following limitations. To
ensure internal validity, this study opted
for the SCCS method, which only included
patients with at least one thromboembolism
during the study period. This may limit the
generalizability of the findings to people
with lower risk of these events even though
our supplementary cohort analysis showed
similar results. If the elevated risk of PE is
truly causal, the estimates that we provided
could be an underestimate. The IRR for the
latest category in the risk interval was still
significantly greater than one, suggesting a
long tail of risk elevation and thus some of
the pre- and post-infection control interval
could be misspecified. Patients with no or
mild symptoms from COVID-19 infection
are less likely to have been tested, especially
at the beginning of the pandemic when
testing capacity was lower. The increased
risk of thromboembolism demonstrated in
the days before confirmed infection is likely
to reflect the time lag between actual date of
infection and our proxy measure of it, which
was the date of specimen collection. Reverse
causation is possible in some patients, for
example, nosocomial infection of patients
hospitalized for thromboembolic events.
However, the lack of an association with
elective surgery suggests that any reverse
causation is unlikely to fully explain our/10.1016/j.mayocp.2021.07.002 2595
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2596findings. The lowered risk in extended pre-
test interval for outcomes except MI also
does not support strong reverse causation.
It is highly likely that there was underreport-
ing of events from the first wave. There were
1465 individuals who died of suspected
COVID-19 (ICD-10, U07.2) without any
tests, suggesting that individuals who had
COVID-19 but were untested were only a
small proportion (4.8%) compared with
those tested and unlikely to change our
conclusion. Although there was no role for
routine computerized tomographic scanning
in COVID-1930 and data on rates of
advanced imaging are not yet clear, it is
our expectation that more extensive imaging
in subsequent waves is highly likely to in-
crease pickup of thrombus.
In conclusion, COVID-19 infection was
associated with substantially elevated risk of
PE andDVT,with excess PE risk lasting at least
8 weeks postinfection. These complications
should be addressed through prophylaxis and
early detection; clinicians should be alerted
to the possibility of PEs in community-
treated patients with residual or prolonged
symptoms. Clinical trials to prevent throm-
botic events should consider the post-
hospital convalescent stage where we have
demonstrated ongoing increased risk in addi-
tion to younger individuals with COVID-19.ACKNOWLEDGMENTS
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